Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06433596

Autologous PRP and Focal Shock Waves for Erectile Dysfunction

Effectiveness and Safety of Autologous Plasma Rich in Platelets and Focal Shock Waves for the Erectile Dysfunction Treatment

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
116 (estimated)
Sponsor
Elexial Research Limited · Academic / Other
Sex
Male
Age
18 Years
Healthy volunteers
Accepted

Summary

The goal of this clinical trial is to learn if Platelet-rich plasma (PRP) combined with Shock-wave therapy (SWT) works to treat moderate or mild to moderate erectile dysfunction. It will also learn about the safety of this combined therapy. The main questions it aims to answer are: * Does Combined therapy PRP + SWT improve erection in men with moderate or mild to moderate erectile dysfunction? * What medical problems do participants have when receiving Combined therapy PRP + SWT? Researchers will compare Combined therapy PRP + SWT to placebo therapy (a look-alike substance that contains no PRP) to see if Combined therapy PRP + SWT works to treat moderate or mild to moderate erectile dysfunction. Participants will: * Take a lab test to evaluate their platelets * Answer some questionnaires to assess your erectile function * Receive Combined therapy PRP + SWT (3 sessions PRP + 6 sessions SWT) or placebo therapy for 9 weeks * Visit the clinic one month, 3 months, and 6 months after finishing the treatment for checkups and tests

Detailed description

The goal of this clinical trial is to evaluate the effectiveness of intracavernosal autologous platelet-rich plasma therapy, compared with placebo, for the treatment of moderate or mild to moderate erectile dysfunction, measured as improvement in the IIEF-EF questionnaire score. Study design: Randomized, double-blind, placebo-controlled clinical trial, phase III. The study will include four groups: * G1 - Autologous PRP: Autologous Platelet Rich Plasma (PRP) + placebo shock waves * G2 - combined therapy: Autologous PRP + focal shock waves * G3 - placebo control: Placebo PRP + placebo shock waves * G4 - shock waves: PRP placebo + shock waves 116 subjects will be included, who will be randomized in a 1:1:1:1 ratio in the four groups described above. The change in the International Index of Erectile Function - Erectile Function domain (IIEF-EF) score, the change in the Erection Hardness Score (EHS), and the adverse events will be evaluated at the end of treatment, and 1, 3, and 6 months of follow-up.

Conditions

Interventions

TypeNameDescription
OTHERPlatelet-rich plasma3 injections of 10 cc of autologous Platelet Rich Plasma (PRP), weeks 1, 5 and 9
OTHERShock waves therapy6 sessions of focal shock waves, 1 per week
OTHERPlacebo PRP3 injections of 10 cc of saline solution, weeks 1, 5 and 9
OTHERSham shock waves therapy6 sessions of sham shock waves, 1 per week

Timeline

Start date
2024-05-06
Primary completion
2026-06-01
Completion
2026-12-01
First posted
2024-05-29
Last updated
2026-02-17

Locations

1 site across 1 country: Spain

Source: ClinicalTrials.gov record NCT06433596. Inclusion in this directory is not an endorsement.